Search | Page 10 | Aplastic Anemia and MDS International Foundation


Search results

  1. A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

    ... . Subjects with intermediate-1, intermediate-2 or high risk MDS by IPSS, and baseline platelet count of <75 Giga (10^9) per liter (Gi/L) ... free during the first 4 cycles of azacitidine therapy. Key secondary endpoints include overall survival, disease response, and disease ...

    Clinical Trial last updated 04/27/2016 - 1:28pm.

  2. CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

    ... . To determine how often primary graft failure and secondary graft failure occurs in the children, adolescents and young adults ... aplastic anemia myelodysplastic syndromes (MDS) Associated Drug(s):  ...

    Clinical Trial last updated 04/28/2016 - 8:36am.

  3. Safety Study of Cord Blood Units for Stem Cell Transplants

    ... administration of unlicensed, investigational NCBP CBU. Secondary Objectives: In patients receiving a non-licensed NCBP CBU ... aplastic anemia myelodysplastic syndromes (MDS) Phase:  Phase 2 ...

    Clinical Trial last updated 04/27/2016 - 2:25pm.

  4. Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

    ... myelodysplastic syndromes (MDS) Phase:  Phase 1 ... but potential risk for adverse events in nursing infants secondary to treatment of the mother with azacitidine, breastfeeding should be ...

    Clinical Trial last updated 05/02/2016 - 2:07pm.

  5. Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic

    ... myelodysplastic syndromes (MDS) Phase:  Phase 2 ... Myeloproliferative neoplasm (MPN) excluding primary or secondary myelofibrosis Adequate organ function defined by: a ...

    Clinical Trial last updated 04/29/2016 - 4:33pm.

  6. Bone Marrow and Stem Cell Transplantation

    ... marrow failure disease like aplastic anemia , MDS or PNH , and your doctor thinks you may be a candidate for a ... , can also affect HSCT outcomes. People with secondary MDS , caused by a previous treatment for another disease or ...

    Page last updated 09/30/2014 - 11:47am.

  7. Joan Latsko, DNP, CRNP, OCN, AOCNP

    ... Joan lectures on myelodysplastic syndromes (MDS) and other relevant hematology disorders at local, state, and ... professional medical conferences. She has been a primary and secondary author in several publications on MDS generated by The Western Pennsylvania Hospital and Cancer Institute. ...

    Bio last updated 03/11/2016 - 1:41pm.

  8. Transplantation


    Page last updated 01/20/2015 - 4:45pm.

  9. Clinical Trials: What Are Phases, and What Happens in Each One?

    ... it’s the first time a drug has been used in someone with MDS. Frequently the drugs we use in a Phase 1 setting are ones that have been ... express purpose of these trials! Drug efficacy is actually a secondary aim in Phase 1 trials, though sometimes we are pleasantly surprised ...

    Interview last updated 11/16/2015 - 8:32am.

  10. MDS: Causes

    What causes MDS? Most experts agree that MDS should be considered a cancer of the blood and bone marrow . Often ... treatments. These can cause treatment-related or secondary MDS . Treatment-related MDS is often severe and can be more ...

    Page last updated 02/25/2015 - 11:31am.